NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate

NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate

Real-time imaging of antibody-drug conjugates (ADCs) offers valuable insights for assessing tumor targeting specificity, monitoring therapeutic efficacy, and detecting off-target accumulation that may cause adverse effects. To enable precise tracking, we developed a versatile fluorescent platform ba...

Full description

Saved in:
Bibliographic Details
Main Author: Elisa Chazeau (14844516) (author)
Other Authors: Angélique Pipier (12890584) (author), K. David Wegner (1775371) (author), François Ghiringhelli (20955797) (author), Lucie Sancey (1355244) (author), Catherine Paul (1585456) (author), Christine Goze (1585465) (author)
Published: 2025
Subjects:
Biochemistry
Molecular Biology
Pharmacology
Biotechnology
Cancer
Space Science
Biological Sciences not elsewhere classified
Chemical Sciences not elsewhere classified
specifically grafted onto
positive subcutaneous tumors
offers valuable insights
monitoring therapeutic efficacy
homogeneous adc suitable
enable precise tracking
mmae selectively accumulated
defined fluorescent adcs
ii optical imaging
ii emitting aza
ii aza
time imaging
therapeutic applications
term tracking
adc allowed
vivo investigations
tumor growth
target accumulation
single injection
significantly reducing
one month
generate well
final step
drug conjugates
bodipy platform
bodipy fluorophore
bodipy dye
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items